CRISPR Therapeutics Gains FDA Pediatric Approval for Casgevy as Sales Hit $76M
Question
CRISPR Therapeutics Gains FDA Pediatric Approval for Casgevy as Sales Hit $76M
Direct answer
CRISPR Therapeutics secured an expanded FDA label for Casgevy to treat pediatric patients aged 2 and older, broadening the total addressable commercial market for the gene-editing therapy. The regulatory milestone coincides with accelerating commercial execution, as Casgevy sales advanced 78% quarter-over-quarter to reach $76 million in the second quarter. — bullish pressure on VRTX.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-09
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “CRISPR Therapeutics Gains FDA Pediatric Approval for Casgevy as Sales Hit $76M”, revision 1, evidence through 2026-09-09. https://marketontology.com/catalysts/2026-09-09/crispr-therapeutics-gains-fda-pediatric-approval-for-casgevy-as-sales-hit-76m-b35862
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| VRTX | ▲Bull | 1–3 months | Policy Shift | 73 |
CRISPR Therapeutics Gains FDA Pediatric Approval for Casgevy as Sales Hit $76M
CRISPR Therapeutics secured an expanded FDA label for Casgevy to treat pediatric patients aged 2 and older, broadening the total addressable commercial market for the gene-editing therapy. The regulatory milestone coincides with accelerating commercial execution, as Casgevy sales advanced 78% quarter-over-quarter to reach $76 million in the second quarter. — bullish pressure on VRTX.
CRISPR Therapeutics secured an expanded FDA label for Casgevy to treat pediatric patients aged 2 and older, broadening the total addressable commercial market for the gene-editing therapy. The regulatory milestone coincides with accelerating commercial execution, as Casgevy sales advanced 78% quarter-over-quarter to reach $76 million in the second quarter.
- SummaryCRISPR Therapeutics secured an expanded FDA label for Casgevy to treat pediatric patients aged 2 and older, broadening the total addressable commercial market for the gene-editing therapy. The regulatory milestone coincides with accelerating commercial execution, as Casgevy sales advanced 78% quarter-over-quarter to reach $76 million in the second quarter.
- VRTXDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- VRTX closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- VRTX price vs. pre-event level
- VRTX volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| VRTX | Bullishdisagreed | 521.12 2026-09-09 | -1.26% | -1.51% | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-09-24Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKDVRTX-2.99%
- 2026-09-24Vertex reports positive Phase IIb inaxaplin results for kidney diseaseVRTX-2.99%
- 2026-09-24Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKDVRTX-2.99%
- 2026-09-24Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease TrialVRTX-2.99%
- 2026-09-24Vertex reports positive Phase IIb inaxaplin results for kidney diseaseVRTX-2.99%
- 2026-09-24Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKDVRTX-2.99%
- 2026-09-24Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease TrialVRTX-2.99%
- 2026-09-24Vertex Reports Positive Phase IIb Kidney Disease Data for InaxaplinVRTX-2.99%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.